cytomegalovirus infection Clinical Trials

29 recruitingLast updated: May 13, 2026

There are 29 actively recruiting cytomegalovirus infection clinical trials across 8 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 4, Phase 3, Early Phase 1. Top locations include Philadelphia, Pennsylvania, United States, Paris, France, New York, New York, United States. Updated daily from ClinicalTrials.gov.


cytomegalovirus infection Trials at a Glance

29 actively recruiting trials for cytomegalovirus infection are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Philadelphia, Paris, and New York. Lead sponsors running cytomegalovirus infection studies include Assistance Publique - Hôpitaux de Paris, Columbia University, and The First Affiliated Hospital of Soochow University.

Browse cytomegalovirus infection trials by phase

Treatments under study

About cytomegalovirus infection Clinical Trials

Looking for clinical trials for cytomegalovirus infection? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new cytomegalovirus infection trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about cytomegalovirus infection clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 29 trials

Recruiting
Phase 1

A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

Congenital Cytomegalovirus Infection
National Institute of Allergy and Infectious Diseases (NIAID)12 enrolled10 locationsNCT06118515
Recruiting
Phase 4

Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationCytomegalovirus Infections+1 more
WeiShi120 enrolled1 locationNCT07569653
Recruiting

Burden of Cytomegalovirus Reactivation in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplantation

cytomegalovirus infectionHematopoietic Stem Cells Transplantation
MSD Italia S.r.l.230 enrolled5 locationsNCT06916195
Recruiting
Phase 2

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

cytomegalovirus infection
ModernaTX, Inc.224 enrolled3 locationsNCT05683457
Recruiting

Breakthrough CMV Lung Transplant -Multicentre

Cytomegalovirus Infections
University of Alberta40 enrolled1 locationNCT04439916
Recruiting
Not Applicable

Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCT

Cytomegalovirus InfectionsCMV
The First Affiliated Hospital of Soochow University330 enrolled1 locationNCT06812598
Recruiting
Phase 3

Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections

cytomegalovirus infection
Assistance Publique - Hôpitaux de Paris80 enrolled5 locationsNCT06334497
Recruiting
Not Applicable

Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

Kidney Transplantation, Cytomegalovirus InfectionsEBV InfectionAntiviral Prophylaxis
National Taiwan University Hospital80 enrolled1 locationNCT07294547
Recruiting
Early Phase 1

T Cell Therapy of Opportunistic Cytomegalovirus Infection

Hematopoietic Stem Cell TransplantCytomegalovirus InfectionsOpportunistic Infections
Mari Dallas20 enrolled1 locationNCT02982902
Recruiting
Phase 3

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Cytomegalovirus InfectionsKidney Transplant InfectionPancreas Transplant
University of Wisconsin, Madison90 enrolled1 locationNCT06407232
Recruiting

Evaluation of Software for Interpreting Virological Results Indicated for the Diagnosis of Cytomegalovirus (CMV) Infection During Pregnancy and Intended for Health Professionals

Cytomegalovirus InfectionsMaternal Primary Cytomegalovirus Infection
Assistance Publique - Hôpitaux de Paris491 enrolled2 locationsNCT06694428
Recruiting
Phase 1Phase 2

Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

Epstein-Barr Virus InfectionsCytomegalovirus InfectionsAdenovirus
Jessie L. Alexander25 enrolled3 locationsNCT06909110
Recruiting
Phase 2

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

Cytomegalovirus InfectionsPrimary Immune Deficiency Disorder
New York Medical College20 enrolled9 locationsNCT03266640
Recruiting
Phase 1

R-MVST Cells for Treatment of Viral Infections in Children and Young Adults

Cytomegalovirus InfectionsImmune DeficiencyBK Virus Infection+2 more
Columbia University18 enrolled1 locationNCT06926894
Recruiting

Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONCytomegalovirus InfectionsTransplant-Related Disorder+1 more
Antonello Di Paolo, M.D., Ph.D.150 enrolled1 locationNCT07013370
Recruiting
Phase 2

Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

Cytomegalovirus InfectionsTransplant-Related Disorder
University of Pennsylvania80 enrolled1 locationNCT06066957
Recruiting
Not Applicable

QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis

Cytomegalovirus Infections
Centre Hospitalier Universitaire de Saint Etienne196 enrolled2 locationsNCT04030676
Recruiting
Phase 4

Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

NeutropeniaCytomegalovirus InfectionsInfection in Solid Organ Transplant Recipients+1 more
Tufts Medical Center25 enrolled1 locationNCT05626530
Recruiting
Phase 2

A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®

Cytomegalovirus InfectionsAdenovirus InfectionEBV+2 more
University Hospital, Basel, Switzerland30 enrolled1 locationNCT02007356
Recruiting
Phase 1

R-MVST Cells for Treatment of Viral Infections

Epstein-Barr Virus InfectionsCytomegalovirus InfectionsBK Virus Infection+1 more
Columbia University36 enrolled1 locationNCT05183490